Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28700501
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Metformin is associated with fewer major adverse cardiac events among patients
with a new diagnosis of type 2 diabetes mellitus: A propensity score-matched
nationwide study
#MMPMID28700501
Lee KT
; Yeh YH
; Chang SH
; See LC
; Lee CH
; Wu LS
; Liu JR
; Kuo CT
; Wen MS
Medicine (Baltimore)
2017[Jul]; 96
(28
): e7507
PMID28700501
show ga
Early type 2 diabetes mellitus (DM) may only require lifestyle modifications for
glycemic control without the need for oral hypoglycemic agents (OHAs). Metformin
is believed to improve cardiovascular outcomes in patients with DM, and it is
considered to be a first-line therapy. However, it is unclear whether metformin
is beneficial for patients with a new diagnosis of DM compared to those who do
not need OHAs for glycemic control.Data were obtained from a population-based
health care database in Taiwan. Patients with a new diagnosis of DM were enrolled
if they received metformin monotherapy only between 1999 and 2010. A 4:1
propensity score-matched cohort of patients with a new diagnosis of DM who did
not take OHAs or insulin during follow-up was also enrolled. The primary study
endpoint was the occurrence of major adverse cardiovascular events (MACEs). The
time to the endpoints was compared between groups using Cox proportional hazards
models.A total of 474,410 patients with DM were enrolled. During a mean 5.8 years
of follow-up, the incidence of MACEs was 1.072% (1072 per 100,000 person-years)
in the metformin monotherapy group versus 1.165% in the lifestyle modification
group (those who did not take OHAs) (P?
|Adolescent
[MESH]
|Adult
[MESH]
|Aged
[MESH]
|Comorbidity
[MESH]
|Databases, Factual
[MESH]
|Diabetes Mellitus, Type 2/complications/diagnosis/*drug therapy/*epidemiology
[MESH]
free
free
free
